Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

The Lancet Haematology - Tập 8 - Trang e879-e890 - 2021
Jacob D Soumerai1, Anthony R Mato2, Ahmet Dogan3, Venkatraman E Seshan4, Erel Joffe3, Kelsey Flaherty3, Jason Carter4, Ephraim Hochberg1, Jeffrey A Barnes1, Audrey M Hamilton3, Jeremy S Abramson1, Connie L Batlevi3, Matthew J Matasar3, Ariela Noy3, Colette N Owens2, M Lia Palomba2, Anita Kumar2, Tak Takvorian1, Ai Ni3, Morgan Choma4
1Massachusetts General Hospital Cancer Center, Boston, MA, USA
2Memorial Sloan Kettering Cancer Center, New York, NY, USA
3Memorial Sloan-Kettering Cancer Center, New York, NY, USA
4Memorial-Sloan Kettering Cancer Center, New York, NY, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Haematology

Tập 8

e879-e890

Thông tin tác giả